Business
Aeglea BioTherapeutics Announces Transition of Chief Financial Officer
AUSTIN, Texas, Feb. 3, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of
About this update from Spyre Therapeutics, Inc.
[{"type":"text","content":"AUSTIN, Texas, Feb. 3, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the company's chief financial officer, Charles N. York II, will be leaving the company effective February 12, 2021 to serve in an expanded chief operating officer and chief financial officer role at an emerging oncology company. \nThe company has initiated a search process to identify a new chief financial officer. Steven Weber, vice president and corporate controller, has been appointed to serve as principal accounting officer and will assume certain key financial responsibilities for Aeglea. The finance and accounting functions will report directly to Anthony Quinn, M.B. Ch.B, Ph.D., Aeglea's president and chief executive officer of Aeglea. Other departments previously reporting to Mr. York will be overseen by members of Aeglea's executive leadership team.\n\"Charles is a highly talented biotech executive with whom I have had the pleasure of working during a transformative period for the Aeglea organization, evolving into a well-financed public company with two clinical-stage programs. Charles has played a key role in helping build a solid organizational foundation and effectively positioning Aeglea as we advance toward becoming a successful commercial-stage company,\" said Dr. Quinn. \"On behalf of the board of directors and the rest of the Aeglea family, I wish Charles the greatest success in his future endeavors and thank him for his leadership and dedication to the company.\"\n\"I am saddened to leave Aeglea and am grateful for the nearly seven years I have spent with the company, seeing it grow from a small team to a clinical-stage biotechnology company preparing for its first commercial launch. This has truly been the experience of a lifetime that has given me the skills and expertise to take this next step in my career,\" said Mr. York. \"I am very proud of the exceptional team we have built and the progress we have made. I sincerely look forward to seeing Aeglea acheive its important upcoming milestones – for both the company and the patients it serves.\"\nAbout Aeglea BioTherapeutics\nAeglea BioTherapeutics is a clinical-stage biotechnology company redefining the p...